US Oncology Announces Proposed Offering of Notes

US Oncology Announces Proposed Offering of Notes 


HOUSTON, July 22  /PRNewswire-FirstCall/ -- US Oncology, Inc. ("US Oncology")
(NASDAQ:USON) announced today that it is commencing an offering under Rule 144A
and Regulation S of up to $200.0 million principal amount of senior notes due
2012 and up to $375.0 million principal amount of senior subordinated notes due
2014.  The net proceeds of the offering, together with amounts borrowed under a
new senior secured credit facility, the proceeds of a cash equity investment by
an investor group led by Welsh, Carson, Anderson & Stowe IX, L.P. ("Welsh
Carson"), and a portion of the cash on hand of US Oncology are intended to be
used to finance US Oncology's previously announced merger with an affiliate of
Welsh Carson, refinance certain existing debt of US Oncology, and pay related
fees and expenses. The simultaneous completion of the merger is one of the
conditions to the offering.  US Oncology anticipates completing the offering in
August 2004.

This announcement is not an offer to sell nor a solicitation of an offer to buy
the securities described herein. US Oncology is offering the notes in reliance
upon exemptions from registration under the Securities Act of 1933 for offers
and sales of securities that do not involve a public offering. The securities
to be offered have not been and will not be registered under the Securities Act
of 1933 or any state securities laws and may not be offered or sold in the
United States absent registration or an applicable exemption from registration
requirements.

This news release contains forward-looking statements based on current
management expectations.  Numerous factors, including those related to market
conditions, and those detailed from time-to-time in the US Oncology's filings
with the Securities and Exchange Commission, may cause results to differ
materially from those anticipated in the forward-looking statements. Many of
the factors that will determine US Oncology's future results are beyond the
ability of US Oncology to control or predict.  These statements are subject to
risks and uncertainties and, therefore, actual results may differ materially.
In particular, the merger is subject to risks and uncertainties, including the
possibility that the merger may not occur due to the failure of US Oncology to
obtain stockholder approval, the failure of the parties to satisfy the
conditions in the merger agreement, such as the inability to obtain financing,
or the occurrence of events that would have a material adverse effect on US
Oncology as described in the merger agreement.  Readers should not place undue
reliance on forward-looking statements, which reflect management's views only
as of the date hereof.  US Oncology undertakes no obligation to revise or
update any forward-looking statements, or to make any other forward-looking
statements, whether as a result of new information, future events or otherwise.


DATASOURCE: US Oncology, Inc.



CONTACT:  Steve Sievert, [phone],  



Web site:  http://www.usoncology.com/

Copyright